Nanomedicine-based potential phyto-drug delivery systems for diabetes

Bahloul, Badr; Henríquez, Luis Castillo; Jenhani, Latifa; Aroua, Nebras; Ftouh, Mahdi; Kalboussi, Nesrine; Vega-Baudrit, José Roberto; Mignet, Nathalie

doi:10.1016/j.jddst.2023.104377

Cited by 7 publications

(7 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Clinical Studiesmentioning

confidence: 99%

“…Studies have shown that, when administered orally, curcumin has a very short halflife (10 min) due to its rapid metabolization, low absorption in the gastro-intestinal tract and rapid excretion [135][136][137][138][139]. In order to boost curcumin activity, its complexation with phospholipids to form phytosomes seems to be the most promising technology, due to the demonstrated improvement in its intestinal absorption and metabolic stability [139]. Recently, it has been shown that a six months treatment with curcumin formulated in phytosomes (Meriva ® , Indena SpA, Milan, Italy, 500 mg tablet × 2/day, equivalent of 100 mg curcuminoids/tablet) significantly reduced plasma pro-inflammatory mediators, such as monocyte chemoattractant protein-1 (MCP-1/CCL-2), IFNγ and IL-4, as well as lipid peroxidation products (thiobarbituric acid reactive substances, TBARS) in chronic kidney disease patients [140].…”

Section: Clinical Studiesmentioning

confidence: 99%

“…Unfortunately, many of these drugs have significant side effects such as fatal hepatotoxicity, increased risk of myocardial infarction and increased cardiovascular mortality (reviewed in [14]). To overcome these problems, alternative or complementary therapeutic strategies with little side effects, such as phytotherapy, were developed [139]. Different complex mixtures or classes of bioactive compounds including alkaloids, flavonoids, polyphenols and triterpenes were used for the amelioration of diabetic symptoms.…”

Section: Diabetes Mellitusmentioning

confidence: 99%

See 2 more Smart Citations

Bioactive Compounds Formulated in Phytosomes Administered as Complementary Therapy for Metabolic Disorders

Toma,

Deleanu,

Sanda

et al. 2024

IJMS

View full text Add to dashboard Cite

Metabolic disorders (MDs), including dyslipidemia, non-alcoholic fatty liver disease, diabetes mellitus, obesity and cardiovascular diseases are a significant threat to human health, despite the many therapies developed for their treatment. Different classes of bioactive compounds, such as polyphenols, flavonoids, alkaloids, and triterpenes have shown therapeutic potential in ameliorating various disorders. Most of these compounds present low bioavailability when administered orally, being rapidly metabolized in the digestive tract and liver which makes their metabolites less effective. Moreover, some of the bioactive compounds cannot fully exert their beneficial properties due to the low solubility and complex chemical structure which impede the passive diffusion through the intestinal cell membranes. To overcome these limitations, an innovative delivery system of phytosomes was developed. This review aims to highlight the scientific evidence proving the enhanced therapeutic benefits of the bioactive compounds formulated in phytosomes compared to the free compounds. The existing knowledge concerning the phytosomes’ preparation, their characterization and bioavailability as well as the commercially available phytosomes with therapeutic potential to alleviate MDs are concisely depicted. This review brings arguments to encourage the use of phytosome formulation to diminish risk factors inducing MDs, or to treat the already installed diseases as complementary therapy to allopathic medication.

show abstract

Section: Clinical Studiesmentioning

confidence: 99%

Section: Clinical Studiesmentioning

confidence: 99%

Section: Diabetes Mellitusmentioning

confidence: 99%

See 1 more Smart Citation

Bioactive Compounds Formulated in Phytosomes Administered as Complementary Therapy for Metabolic Disorders

Toma,

Deleanu,

Sanda

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…10 For instance, solid lipid nanoparticles frequently encounter obstacles such as drug leakage and suboptimal loading efficiency, a consequence of the limited spatial capacity inherent in their lipid matrix structure. 11 In the case of nanoemulsions, their reduced particle size is often a double-edged sword, leading to a compromised stability. Metal nanoparticles, while benefiting from chemical stability, are plagued by complications in their synthesis, the costliness of materials, and a tendency toward aggregation.…”

Section: Introductionmentioning

confidence: 99%

“…Despite these advantages, challenges still persist . For instance, solid lipid nanoparticles frequently encounter obstacles such as drug leakage and suboptimal loading efficiency, a consequence of the limited spatial capacity inherent in their lipid matrix structure . In the case of nanoemulsions, their reduced particle size is often a double-edged sword, leading to a compromised stability.…”

Section: Introductionmentioning

confidence: 99%

Morin-Based Nanoparticles for Regulation of Blood Glucose

Hua,

Li,

Chen

et al. 2024

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Morin, a naturally occurring bioactive compound shows great potential as an antioxidant, anti-inflammatory agent, and regulator of blood glucose levels. However, its low water solubility, poor lipid solubility, limited bioavailability, and rapid clearance in vivo hinder its application in blood glucose regulation. To address these limitations, we report an enzymatically synthesized nanosized morin particle (MNs) encapsulated in sodium alginate microgels (M@SA). This approach significantly enhances morin's delivery efficiency and therapeutic efficacy in blood glucose regulation. Utilizing horseradish peroxidase, we synthesized MNs averaging 305.7 ± 88.7 nm in size. These MNs were then encapsulated via electrohydrodynamic microdroplet spraying to form M@SA microgels. In vivo studies revealed that M@SA microgels demonstrated prolonged intestinal retention and superior efficacy compared with unmodified morin and MNs alone. Moreover, MNs notably improved glucose uptake in HepG2 cells. Furthermore, M@SA microgels effectively regulated blood glucose, lipid profiles, and oxidative stress in diabetic mice while mitigating liver, kidney, and pancreatic damage and enhancing antiinflammatory responses. Our findings propose a promising strategy for the oral administration of natural compounds for blood glucose regulation, with implications for broader therapeutic applications.

show abstract

Synergistic Strategies of Biomolecular Transport Technologies in Transdermal Healthcare Systems

Han,

Choi,

Kang

2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Transdermal healthcare systems have gained significant attention for their painless and convenient drug administration, as well as their ability to detect biomarkers promptly. However, the skin barrier limits the candidates of biomolecules that can be transported, and reliance on simple diffusion poses a bottleneck for personalized diagnosis and treatment. Consequently, recent advancements in transdermal transport technologies have evolved toward active methods based on external energy sources. Multiple combinations of these technologies have also shown promise for increasing therapeutic effectiveness and diagnostic accuracy as delivery efficiency is maximized. Furthermore, wearable healthcare platforms are being developed in diverse aspects for patient convenience, safety, and on‐demand treatment. Herein, a comprehensive overview of active transdermal delivery technologies is provided, highlighting the combination‐based diagnostics, therapeutics, and theragnostics, along with the latest trends in platform advancements. This offers insights into the potential applications of next‐generation wearable transdermal medical devices for personalized autonomous healthcare.

show abstract

Nanomedicine-based potential phyto-drug delivery systems for diabetes

Cited by 7 publications

References 84 publications

Bioactive Compounds Formulated in Phytosomes Administered as Complementary Therapy for Metabolic Disorders

Bioactive Compounds Formulated in Phytosomes Administered as Complementary Therapy for Metabolic Disorders

Morin-Based Nanoparticles for Regulation of Blood Glucose

Synergistic Strategies of Biomolecular Transport Technologies in Transdermal Healthcare Systems

Contact Info

Product

Resources

About